Regulation of Microglia for the Treatment of Glioma

Zhou, Shaoman; Cisse, Babacar

doi:10.1016/j.wneu.2021.06.107

Cited by 1 publication

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignant glioma cells/GSCs and microglia/macrophages have an intricate relationship and targeting several synergistic mechanisms at once seems particularly attractive. Moreover, modifying microglia directly for the treatment of glioma may provide novel access to glioblastoma and other high grade gliomas [ 216 ]. The therapeutic potential of targeting tumour associated microglia/brain macrophages has been the topic of a number of recent review articles [ 217 , 218 , 219 ].…”

Section: Discussionmentioning

confidence: 99%

Microglia and Brain Macrophages as Drivers of Glioma Progression

Zheng

Graeber

2022

IJMS

View full text Add to dashboard Cite

Evidence is accumulating that the tumour microenvironment (TME) has a key role in the progression of gliomas. Non-neoplastic cells in addition to the tumour cells are therefore finding increasing attention. Microglia and other glioma-associated macrophages are at the centre of this interest especially in the context of therapeutic considerations. New ideas have emerged regarding the role of microglia and, more recently, blood-derived brain macrophages in glioblastoma (GBM) progression. We are now beginning to understand the mechanisms that allow malignant glioma cells to weaken microglia and brain macrophage defence mechanisms. Surface molecules and cytokines have a prominent role in microglia/macrophage-glioma cell interactions, and we discuss them in detail. The involvement of exosomes and microRNAs forms another focus of this review. In addition, certain microglia and glioma cell pathways deserve special attention. These “synergistic” (we suggest calling them “Janus”) pathways are active in both glioma cells and microglia/macrophages where they act in concert supporting malignant glioma progression. Examples include CCN4 (WISP1)/Integrin α6β1/Akt and CHI3L1/PI3K/Akt/mTOR. They represent attractive therapeutic targets.

show abstract